-
Mashup Score: 30Lung cancer diagnoses on the rise among never-smokers worldwide - 1 month(s) ago
Research shows need for further studies into air pollution and other causal factors, expert says
Source: www.theguardian.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Thrombotic Thrombocytopenic Purpura: History • The Blood Project - 1 month(s) ago
Note: until the discovery and incorporation of ADAMTS13 into the definition of TTP, it is not possible to know how many of the previous cases in the
Source: www.thebloodproject.comCategories: General Medicine News, Hem/OncsTweet-
RT @WilliamAird4: HISTORY OF TTP For full discussion, see: https://t.co/stsIILNEBh https://t.co/R9bYeKFh2q
-
-
Mashup Score: 29Lung cancer diagnoses on the rise among never-smokers worldwide - 1 month(s) ago
Research shows need for further studies into air pollution and other causal factors, expert says
Source: www.theguardian.comCategories: General Medicine News, Hem/OncsTweet-
RT @FordePatrick: Lung cancer diagnoses on the rise among never-smokers worldwide | Lung cancer | The Guardian https://t.co/UubliT4H3E
-
-
Mashup Score: 33
Virchows Archiv – With the explosion in knowledge about the molecular landscape of lymphoid malignancies and the increasing availability of high throughput techniques, molecular diagnostics in…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet-
RT @thejourneymate: A Diagnostic Approach to the use of FISH in Aggressive B-Cell Lymphomas 🔬 https://t.co/QEGssnDUpn https://t.co/w63d3JOV…
-
-
Mashup Score: 4Histology Agnostic Drug Development: An Updated Review - 4 month(s) ago
Recent advancements in oncology have led to the development of histology-agnostic therapies, which target genetic alterations irrespective of the tumor’s tissue of origin. This review aimed to provide a comprehensive update on the current state of histology-agnostic drug development, focusing on key therapies, including pembrolizumab, larotrectinib, entrectinib, dostarlimab, dabrafenib plus trametinib, selpercatinib, trastuzumab deruxtecan, and reprotrectinib. We performed a detailed analysis of each therapy’s mechanism of action, clinical trial outcomes, and associated biomarkers. The review further explores challenges in drug resistance, such as adaptive signaling pathways and neoantigen variability, as well as diagnostic limitations in identifying optimal patient populations. While these therapies have demonstrated efficacy in various malignancies, significant hurdles remain, including intratumoral heterogeneity and resistance mechanisms that diminish treatment effectiveness. We pro
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
✔️ Histology Agnostic Drug Development: An Updated Review - Kevin Nguyen, Karina Fama, Guadalupe Mercado, Yin Myat @Cancers_MDPI @TouroNevada @CCCNevada https://t.co/BA8QxQfmQD #mdpicancers via @Cancers_MDPI
-
-
Mashup Score: 14Systemic Therapy Options for Peritoneal Mesothelioma - 5 month(s) ago
Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials conducted among patients with pleural mesothelioma. At present, the recommended first-line systemic treatment options may include immunotherapy with nivolumab plus ipilimumab or chemotherapy with pemetrexed plus either cisplatin or carboplatin. For second-line treatment, the other previously unchosen first-line option can be used. Off-label bevacizumab may be considered in combination with chemotherapy among carefully selected patients. The benefit of third-line treatment or beyond is less clear. Nonetheless, a number of single-agent regimens show modest activity. Anecdotal reports of children or young adults with peritoneal mesothelioma harboring ALK rearrangement have suggested the efficac
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet-
RT @Erman_Akkus: 📘Systemic Therapy Options for Peritoneal Mesothelioma @JNCCN 👉https://t.co/sKh1sBB7ij @NCCN @OncoAlert #cancer #Oncolog…
-
-
Mashup Score: 159Molecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification - 5 month(s) ago
In 2022, the new WHO Classification of Endocrine and Neuroendocrine Tumors, Fifth Edition (beta version) (WHO 5th), was published. Large-scale genomic analyses such as The Cancer Genome Atlas (TCGA) have revealed the importance of understanding the molecular genetics of thyroid tumors. Consequently, the WHO 5th was fundamentally revised, resulting in a systematic classification based on the cell of origin of tumors and their clinical risk. This paper outlines the following critical points of the WHO 5th. 1. Genetic mutations in follicular cell-derived neoplasms (FDNs) highlight the role of mutations in the MAP kinase pathway, including RET, RAS, and BRAF, as drivers of carcinogenesis. Differentiated thyroid cancers such as follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) have specific genetic alterations that correlate with morphological classifications: RAS-like tumors (RLTs) and BRAF p.V600E-like tumors (BLTs), respectively. 2. The framework for benign lesions
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
RT @thejourneymate: Algorithm for Diagnosis of Thyroid Tumors 🔬 (2022 WHO 5th edition) https://t.co/1pv8YawPAz https://t.co/FuWmeImkYP
-
-
Mashup Score: 6Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions - 5 month(s) ago
NTRK fusions are oncogenic drivers for multiple tumor types. Therefore, the development of selective tropomyosin receptor kinase (TRK) inhibitors, including larotrectinib and entrectinib, has been transformative in the context of clinical management, given the high rates of responses to these drugs, including intracranial responses in patients with brain metastases. Given their promising activity in pan-cancer cohorts, larotrectinib and entrectinib received U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for tissue-agnostic indications in patients with advanced solid tumors harboring NTRK fusions. The safety profiles for both drugs are quite manageable, although neurotoxicity driven by the on-target inhibition of normal NTRK can be a concern. Also, on- and off-target resistance mechanisms can arise during therapy with TRK inhibitors, but they can be addressed with the use of combination therapy and next-generation TRK inhibitors. More recently, the
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions @mgoudaMD @DavidHongMD https://t.co/EjouB3Yd21 #mdpicancers via @Cancers_MDPI @MDAndersonNews @CCCNevada @unlvmedicine
-
-
Mashup Score: 82Flowcharts - 6 month(s) ago
Publisher efficient Urology learning materials. Our books let Urologists focus on what matters.
Source: knowuro.comCategories: General Medicine News, Hem/OncsTweet-
RT @knowuro: Hello #urologists and #oncologists! Our uro-oncology flowcharts are now available on our website: https://t.co/dvm6yjXInn…
-
-
Mashup Score: 3
The regulatory approvals of tumor-agnostic therapies have led to the re-evaluation of the drug development process. The conventional models of drug development are histology-based. On the other hand, the tumor-agnostic drug development of a new drug (or combination) focuses on targeting a common genomic biomarker in multiple cancers, regardless of histology. The basket-like clinical trials with multiple cohorts allow clinicians to evaluate pan-cancer efficacy and toxicity. There are currently eight tumor agnostic approvals granted by the Food and Drug Administration (FDA). This includes two immune checkpoint inhibitors, and five targeted therapy agents. Pembrolizumab is an anti-programmed cell death protein-1 (PD-1) antibody that was the first FDA-approved tumor-agnostic treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) solid tumors in 2017. It was later approved for tumor mutational burden-high (TMB-H) solid tumors, al
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development - Shivaani Kummar, Byung Park, Kalpana Panigrahi, Yin Myat https://t.co/xpNbPQO3so @Cancers_MDPI @MDPIOpenAccess @CCCNevada @unlvmedicine @TouroNevada @OHSUKnight @OHSUSOM @OnebrooklynH
-
RT @FordePatrick: Lung cancer diagnoses on the rise among never-smokers worldwide | Lung cancer | The Guardian https://t.co/UubliT4H3E